本帖最后由 老马 于 2012-1-13 21:20 编辑 & u8 Q" {: g; H& y$ n g
% J; {' a- {% F$ z
爱必妥和阿瓦斯丁的比较+ S6 V& N. w' L* J9 v. `
# p2 V6 h1 U$ X- |3 ?
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
' a$ n, ?* A L" X( U
/ {1 B9 ?4 I V# P. h' o
; w% T; _! U! R9 N! X# f& ~+ M N: y
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/& }5 a/ l. k+ a% F/ }
==================================================2 ] a) a, K% n [1 l8 P
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, Q6 j' O) S6 ^& S$ e" g8 jPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. U0 e: F1 A( b2 b yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.4 \1 B& G5 k( a3 l$ g5 E5 a
|